Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 45

1.

Germline genetic profiling in prostate cancer: latest developments and potential clinical applications.

Ahmed M, Eeles R.

Future Sci OA. 2015 Dec 18;2(1):FSO87. doi: 10.4155/fso.15.87. eCollection 2016 Mar. Review.

2.

Whole exome sequencing in 75 high-risk families with validation and replication in independent case-control studies identifies TANGO2, OR5H14, and CHAD as new prostate cancer susceptibility genes.

Karyadi DM, Geybels MS, Karlins E, Decker B, McIntosh L, Hutchinson A, Kolb S, McDonnell SK, Hicks B, Middha S, FitzGerald LM, DeRycke MS, Yeager M, Schaid DJ, Chanock SJ, Thibodeau SN, Berndt SI, Stanford JL, Ostrander EA.

Oncotarget. 2017 Jan 3;8(1):1495-1507. doi: 10.18632/oncotarget.13646.

3.

HOXB13 and other high penetrant genes for prostate cancer.

Pilie PG, Giri VN, Cooney KA.

Asian J Androl. 2016 Jul-Aug;18(4):530-2. doi: 10.4103/1008-682X.175785. No abstract available.

4.

A comparison of genetic risk score with family history for estimating prostate cancer risk.

Helfand BT.

Asian J Androl. 2016 Jul-Aug;18(4):515-9. doi: 10.4103/1008-682X.177122. Review.

5.

Germline Variants in Asporin Vary by Race, Modulate the Tumor Microenvironment, and Are Differentially Associated with Metastatic Prostate Cancer.

Hurley PJ, Sundi D, Shinder B, Simons BW, Hughes RM, Miller RM, Benzon B, Faraj SF, Netto GJ, Vergara IA, Erho N, Davicioni E, Karnes RJ, Yan G, Ewing C, Isaacs SD, Berman DM, Rider JR, Jordahl KM, Mucci LA, Huang J, An SS, Park BH, Isaacs WB, Marchionni L, Ross AE, Schaeffer EM.

Clin Cancer Res. 2016 Jan 15;22(2):448-58. doi: 10.1158/1078-0432.CCR-15-0256. Epub 2015 Oct 7.

6.

Fine-mapping the 2q37 and 17q11.2-q22 loci for novel genes and sequence variants associated with a genetic predisposition to prostate cancer.

Laitinen VH, Rantapero T, Fischer D, Vuorinen EM, Tammela TL; PRACTICAL Consortium, Wahlfors T, Schleutker J.

Int J Cancer. 2015 May 15;136(10):2316-27. doi: 10.1002/ijc.29276. Epub 2014 Nov 8.

7.

Dysregulation of the homeobox transcription factor gene HOXB13: role in prostate cancer.

Decker B, Ostrander EA.

Pharmgenomics Pers Med. 2014 Aug 5;7:193-201. doi: 10.2147/PGPM.S38117. eCollection 2014. Review.

8.

Mutational landscape of candidate genes in familial prostate cancer.

Johnson AM, Zuhlke KA, Plotts C, McDonnell SK, Middha S, Riska SM, Schaid DJ, Thibodeau SN, Douglas JA, Cooney KA.

Prostate. 2014 Oct;74(14):1371-8. doi: 10.1002/pros.22849. Epub 2014 Aug 11.

9.

Fine-mapping the HOXB region detects common variants tagging a rare coding allele: evidence for synthetic association in prostate cancer.

Saunders EJ, Dadaev T, Leongamornlert DA, Jugurnauth-Little S, Tymrakiewicz M, Wiklund F, Al Olama AA, Benlloch S, Neal DE, Hamdy FC, Donovan JL, Giles GG, Severi G, Gronberg H, Aly M, Haiman CA, Schumacher F, Henderson BE, Lindstrom S, Kraft P, Hunter DJ, Gapstur S, Chanock S, Berndt SI, Albanes D, Andriole G, Schleutker J, Weischer M, Nordestgaard BG, Canzian F, Campa D, Riboli E, Key TJ, Travis RC, Ingles SA, John EM, Hayes RB, Pharoah P, Khaw KT, Stanford JL, Ostrander EA, Signorello LB, Thibodeau SN, Schaid D, Maier C, Kibel AS, Cybulski C, Cannon-Albright L, Brenner H, Park JY, Kaneva R, Batra J, Clements JA, Teixeira MR, Xu J, Mikropoulos C, Goh C, Govindasami K, Guy M, Wilkinson RA, Sawyer EJ, Morgan A; COGS-CRUK GWAS-ELLIPSE (Part of GAME-ON) Initiative; UK Genetic Prostate Cancer Study Collaborators; UK ProtecT Study Collaborators; PRACTICAL Consortium, Easton DF, Muir K, Eeles RA, Kote-Jarai Z.

PLoS Genet. 2014 Feb 13;10(2):e1004129. doi: 10.1371/journal.pgen.1004129. eCollection 2014 Feb.

10.

A population-based analysis of clustering identifies a strong genetic contribution to lethal prostate cancer.

Nelson Q, Agarwal N, Stephenson R, Cannon-Albright LA.

Front Genet. 2013 Aug 20;4:152. doi: 10.3389/fgene.2013.00152. eCollection 2013.

11.

ARLTS1 and prostate cancer risk--analysis of expression and regulation.

Siltanen S, Fischer D, Rantapero T, Laitinen V, Mpindi JP, Kallioniemi O, Wahlfors T, Schleutker J.

PLoS One. 2013 Aug 5;8(8):e72040. doi: 10.1371/journal.pone.0072040. Print 2013.

12.

Prostate cancer risk-associated genetic markers and their potential clinical utility.

Xu J, Sun J, Zheng SL.

Asian J Androl. 2013 May;15(3):314-22. doi: 10.1038/aja.2013.42. Epub 2013 Apr 8.

13.

The expression level of miR-18b in hepatocellular carcinoma is associated with the grade of malignancy and prognosis.

Murakami Y, Tamori A, Itami S, Tanahashi T, Toyoda H, Tanaka M, Wu W, Brojigin N, Kaneoka Y, Maeda A, Kumada T, Kawada N, Kubo S, Kuroda M.

BMC Cancer. 2013 Mar 4;13:99. doi: 10.1186/1471-2407-13-99.

14.

HOXB13 mutation and prostate cancer: studies of siblings and aggressive disease.

Witte JS, Mefford J, Plummer SJ, Liu J, Cheng I, Klein EA, Rybicki BA, Casey G.

Cancer Epidemiol Biomarkers Prev. 2013 Apr;22(4):675-80. doi: 10.1158/1055-9965.EPI-12-1154. Epub 2013 Feb 8.

15.

Familial prostate cancer: the damage done and lessons learnt.

Taherian N, Hamel N, Bégin LR, Bismar TA, Goldgar DE, Feng BJ, Foulkes WD.

Nat Rev Urol. 2013 Feb;10(2):116-22. doi: 10.1038/nrurol.2012.257. Epub 2013 Jan 15.

16.

HOXB13 mutations in a population-based, case-control study of prostate cancer.

Stott-Miller M, Karyadi DM, Smith T, Kwon EM, Kolb S, Stanford JL, Ostrander EA.

Prostate. 2013 May;73(6):634-41. doi: 10.1002/pros.22604. Epub 2012 Nov 5.

17.

HOXB13 is a susceptibility gene for prostate cancer: results from the International Consortium for Prostate Cancer Genetics (ICPCG).

Xu J, Lange EM, Lu L, Zheng SL, Wang Z, Thibodeau SN, Cannon-Albright LA, Teerlink CC, Camp NJ, Johnson AM, Zuhlke KA, Stanford JL, Ostrander EA, Wiley KE, Isaacs SD, Walsh PC, Maier C, Luedeke M, Vogel W, Schleutker J, Wahlfors T, Tammela T, Schaid D, McDonnell SK, DeRycke MS, Cancel-Tassin G, Cussenot O, Wiklund F, Grönberg H, Eeles R, Easton D, Kote-Jarai Z, Whittemore AS, Hsieh CL, Giles GG, Hopper JL, Severi G, Catalona WJ, Mandal D, Ledet E, Foulkes WD, Hamel N, Mahle L, Moller P, Powell I, Bailey-Wilson JE, Carpten JD, Seminara D, Cooney KA, Isaacs WB; International Consortium for Prostate Cancer Genetics.

Hum Genet. 2013 Jan;132(1):5-14. doi: 10.1007/s00439-012-1229-4. Epub 2012 Oct 12.

18.

Mitochondrial haplogroups and polymorphisms reveal no association with sporadic prostate cancer in a southern European population.

Álvarez-Cubero MJ, Saiz Guinaldo M, Martínez-González LJ, Álvarez Merino JC, Cózar Olmo JM, Acosta JA.

PLoS One. 2012;7(7):e41201. doi: 10.1371/journal.pone.0041201. Epub 2012 Jul 17.

19.

Confirmation of the HOXB13 G84E germline mutation in familial prostate cancer.

Breyer JP, Avritt TG, McReynolds KM, Dupont WD, Smith JR.

Cancer Epidemiol Biomarkers Prev. 2012 Aug;21(8):1348-53. doi: 10.1158/1055-9965.EPI-12-0495. Epub 2012 Jun 19.

20.

Germline mutations in HOXB13 and prostate-cancer risk.

Ewing CM, Ray AM, Lange EM, Zuhlke KA, Robbins CM, Tembe WD, Wiley KE, Isaacs SD, Johng D, Wang Y, Bizon C, Yan G, Gielzak M, Partin AW, Shanmugam V, Izatt T, Sinari S, Craig DW, Zheng SL, Walsh PC, Montie JE, Xu J, Carpten JD, Isaacs WB, Cooney KA.

N Engl J Med. 2012 Jan 12;366(2):141-9. doi: 10.1056/NEJMoa1110000.

Supplemental Content

Support Center